Flexible Bio-therapeutic Infrastructure
On March 6, 2008, DARPA's S DSO opened solicitations for "the demonstration of innovative concepts and technologies for just-in-time flexible bio-therapeutic infrastructure resources..." http://www.darpa.mil/dso/solicitations/SN08-14.pdf
Sixth Horizon This is a stub article. Please make it better by adding to it! Especially if you have information that this item is closer to development or deployment than this solicitation suggests.
According to DARPA's DSO:
" The Defense Sciences Office (DSO) of the Defense Advanced Research Projects Agency is seeking the demonstration of innovative concepts and technologies for just-in-time flexible biotherapeutic infrastructure resources at 10,000-dose scale (e.g., 90 μg/dose vaccine, 400 mg/dose mAb). The goal of this RFI is to identify portable, minimal footprint technologies that satisfy the dual requirements of extreme low cost development and high capacity production for therapeutic vaccines or monoclonal antibodies within an abbreviated timeframe.
Specially, DSO seeks the following capabilities and technologies:
"1. Flexible systems: Single use, integrated and automated solutions that meet the metabolic demands of diverse, engineered, and transiently expressed protein expression systems. DARPA is interested in new technologies that exceed current capabilities used to support the growth of substrates for diverse expression systems including prokaryotes, yeast, fungus, and algae. DARPA is not specifically interested in systems used for mammalian cell-based protein expression.
"2. Ultra-low cost: Reduced costs associated with protein expression systems, such as reduced bioreactor equipment costs, operation costs, media requirements and independence from purpose-built facilities and infrastructure. The low cost of materials would allow for the rapid conversion of the bioreactors to on-demand production of biological countermeasures.
"3. Current Good Manufacturing Practices (cGMP): Capabilities and plans for quality control measures, as well as mitigation strategies.
"4. Deployment: Minimal reliance on local resources, human capital, and critical reagent supply, as well as a minimal need for user expertise (typical of a Combat Support Hospital)."
http://www.darpa.mil/dso/solicitations/SN08-14.pdf
http://www.darpa.mil/dso/solicitations/SN08-14.pdf
This is a stub article. Please make it better by adding to it!
Comments (0)
You don't have permission to comment on this page.